Northwestern Medicine studies Apple Watch to change AFib treatment
- Northwestern Medicine is conducting a health study using Apple Watches for patients with atrial fibrillation (AFib).
- Participants will be randomized to receive either standard care with daily blood thinners or use a new app-based approach on the Apple Watch.
- The study could potentially improve patient quality of life and reduce the risks and costs associated with long-term blood thinner use.
In the United States, Northwestern Medicine has initiated a health study aimed at improving the treatment for atrial fibrillation (AFib), a prevalent type of heart arrhythmia. This condition is characterized by rapid and irregular heartbeats originating from the heart's atria, which significantly increases the risks associated with strokes, heart failure, and early mortality. Traditionally, patients suffering from AFib have been required to take blood thinners for life as a means of managing their condition. However, while these medications are effective, they also come with significant risks, primarily the dangers associated with excessive bleeding. The groundbreaking trial, which is set to last seven years, looks to recruit participants from over 80 sites across the nation. The study will involve two groups; one will continue with the current standard of care that involves regular daily consumption of blood thinners, while the other group will utilize a novel